SEC Form 4	
------------	--

 \Box

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) (First) (Middle) 04/13/2023 Image: Comparison of the comp	1. Name and Address of Reporting Person [*] ORBIMED ADVISORS LLC					2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner								
	(Last)	(First)	(Middl	e)									Other (specify pelow)	
(Street) NEW YORK NY 10022 X Form filed by More than One Reporting Person (Street) (City) (State) (Zip) Rule 10b5-1(c) TURE SUBJICATION INCLOSES Table 1 - Von-Derivative Acquired Line at transaction of Rule 1005-1(c). See Instruction 10. Table 1 - Von-Derivative Acquired Line at transaction of Rule 1005-1(c). See Instruction 10. Table 1 - Von-Derivative Acquired Line at transaction of Rule 1005-1(c). See Instruction 10. Table 1 - Von-Derivative Acquired Line at transaction of Rule 1005-1(c). See Instruction 10. Securities Acquired (A) or Securities Acquired (A) or Securities Acquired (A) or Securities. The Portein Transaction (Street Instruction Attent (Street Instructin (Street Instruction Attent (Street Instruction (Stre	601 LEXINGT	ON AVENUE, 547	TH FL	OOR	4.1									heck Applicable
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		NY	1002	2								Y Form filed b	, ,	0
Table I - Non-Derivative Securities Acquired, NorthSecurities Acquired, North1. Title of Security (Instr. 3) $\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	(City)	(State)	(Zip)		R	Rule 10b5-1(c) Transaction Indication				on				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Deemed Execution Date, (Month/Day/Year) 3. A Deemed Execution Date, (Month/Day/Year) 4. Securities Acquired (A) or bisposed Of (D) (Instr. 3, 4 and bisposed Of (D) (Instr. 4) (Instr. 4) 5. Amount of bisposed Of (D) (Instr. 3, 4 and bisposed Of (D) (Instr. 3, 4 and bisposed Of (D) (Instr. 4) (Instr. 4) (Instr. 4) 5. Ownership Energical Downership (Instr. 4) Common Stock 04/13/2023 S 7.03 D \$1.82 182,504 I See footnote footno						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								t is intended to
Date (Month/Day/Year)Execution Date, (fany) (Month/Day/Year)Execution Date, (fany) (Month/Day/Year)Firansaction (Code (a)Disposed Of (D) (Instr. 3, 4 and (b) of (D)Securities (D) of Indirectal (D) or Indirectal (D) (Instr. 4)Form: Direct (D) (Instr. 4)Form: Direct (D) (Instr. 4)Form: Direct (D) (Instr. 4)Form: Direct 		Tab	ole I - I	Non-Deriva	tive	e Securities A	cquir	ed, C)isposed (of, or l	Benefic	cially Owned		
Image: Condensity of the state of the sta	1. Title of Security	Date		Date	- 1	Execution Date, if any	Transaction Code (Instr.		n Disposed Of (D) (Instr. 3, 4 a			I Securities Beneficially Owned Following	Form: Direct (D) or Indirect	Beneficial Ownership
Common Stock04/13/2023S703D\$1.82182,504IfootnoteCommon Stock04/13/2023S\$3,784D\$1.82981,863ISee footnoteCommon Stock04/13/2023S\$9,459D\$1.822,454,775ISee footnoteCommon Stock04/14/2023S\$2,091D\$1.86180,413ISee footnoteCommon Stock04/14/2023S\$11,245D\$1.86970,618ISee footnoteCommon Stock04/14/2023S\$\$\$1.822,426,665ISee footnoteCommon Stock04/14/2023S\$\$\$1.82\$1.86							Code	v	Amount	(A) or (D)	Price	Transaction(s)		(Instr. 4)
Common Stock04/13/2023SS3,784D\$1.82981,863IfootnoteCommon Stock04/13/2023SS9,459D\$1.822,454,775ISee footnoteCommon Stock04/14/2023SS2,091D\$1.86180,413ISee footnoteCommon Stock04/14/2023SSI1,245D\$1.86970,618ISee footnoteCommon Stock04/14/2023SSS660D\$1.862,426,665ISee footnoteCommon Stock04/14/2023SS660D\$1.862,426,665ISee footnote	Common Stock			04/13/2023	3		S		703	D	\$1.82	182,504	I	See footnotes ⁽¹⁾⁽⁴⁾
Common Stock04/13/2023ss9,459D\$1.822,454,775IfootnoteCommon Stock04/14/2023ss2,091D\$1.86180,413ISee footnoteCommon Stock04/14/2023ss11,245D\$1.86970,618ISee footnoteCommon Stock04/14/2023ss28,110D\$1.862,426,665ISee footnoteCommon Stock04/17/2023ss660D\$1.97179,753ISee 	Common Stock			04/13/2023	3		S		3,784	D	\$1.82	981,863	I	See footnotes ⁽²⁾⁽⁴⁾
Common Stock04/14/2023ss2,091D\$1.86180,413IfootnoteCommon Stock04/14/2023ss11,245D\$1.86970,618ISee footnoteCommon Stock04/14/2023ss28,110D\$1.862,426,665ISee footnoteCommon Stock04/17/2023ss660D\$1.97179,753JSee footnote	Common Stock			04/13/2023	3		s		9,459	D	\$1.82	2,454,775	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock 04/14/2023 S 11,245 D \$1.86 970,618 I footnote Common Stock 04/14/2023 S 28,110 D \$1.86 970,618 I \$60 footnote Common Stock 04/14/2023 S 28,110 D \$1.86 2,426,665 I \$60 footnote Common Stock 04/17/2023 S 660 D \$197 179,753 I \$60 footnote	Common Stock			04/14/2023	3		s		2,091	D	\$1.86	180,413	I	See footnotes ⁽¹⁾⁽⁴⁾
Common Stock 04/14/2023 s 28,110 D \$1.86 2,426,665 I footnote Common Stock 04/17/2023 S 660 D \$1.97 179,753 I See	Common Stock			04/14/2023	3		S		11,245	D	\$1.86	970,618	I	See footnotes ⁽²⁾⁽⁴⁾
1 Common Stock 1 04/17/2023 1 1 S 1 660 1 D 1 S1 97 1 179 753 1 1 1	Common Stock			04/14/2023	3		S		28,110	D	\$1.86	2,426,665	I	See footnotes ⁽³⁾⁽⁴⁾
footnote	Common Stock			04/17/2023	3		s		660	D	\$1.97	179,753	I	See footnotes ⁽¹⁾⁽⁴⁾
Common Stock04/17/2023ss3,551D\$1.97967,067ISee footnote	Common Stock			04/17/2023	3		S		3,551	D	\$1.97	967,067	I	See footnotes ⁽²⁾⁽⁴⁾
Common Stock04/17/2023ss8,878D\$1.972,417,787ISee footnote	Common Stock			04/17/2023	3		S		8,878	D	\$1.97	2,417,787	I	See footnotes ⁽³⁾⁽⁴⁾

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Disp of (D	or osed) r. 3, 4	Expiration Date		Expiration Date (Month/Day/Year)		ate Amount of		nt of Derivative der tites Security Sec lying (Instr. 5) Ber tive Ow ty (Instr. 4000 - 1000 -		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
1. Name a	nd Address of	Reporting Person*															

ORBIMED ADVISORS LLC

,		
(Last)	(First)	(Middle)

601 LEXINGTON AVENUE, 54TH FLOOR

10022

(Street)		
NEW YORK	NY	

(City)	(State)	(Zip)					
1. Name and Address of Reporting Person [*] OrbiMed Genesis GP LLC							
(Last) 601 LEXINGTON	(First) AVENUE, 54TH FI	(Middle) LOOR					
,							
(Street) NEW YORK	NY	10022					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person [*] OrbiMed Israel GP II, L.P.							
(Last)	(First)	(Middle)					
5 HAHOSHLIM S BUILDING B, 1S							
(Street) HERZLIYA PITUACH	L3	4614001					
(City)	(State)	(Zip)					
	1. Name and Address of Reporting Person [*] OrbiMed Advisors Israel II Ltd						
(Last)	(First)	(Middle)					
5 HAHOSHLIM S BUILDING B, 1S							
(Street) HERZLIYA PITUACH	L3	4614001					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person [*] OrbiMed Capital GP VII LLC							
(Last) 601 LEXINGTON	(Last) (First) (Middle) 601 LEXINGTON AVENUE, 54TH FLOOR						
(Street) NEW YORK	NY	10022					
(City)	(State)	(Zip)					

Explanation of Responses:

1. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP, by virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power hrough a management comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

2. These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

3. These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

4. Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC	04/17/2023
<u>/s/ Carl L. Gordon, Member of</u> <u>OrbiMed Genesis GP LLC</u>	04/17/2023
<u>/s/ Carl L. Gordon, Director of</u> <u>OrbiMed Israel GP II, L.P.</u>	04/17/2023
	<u>04/17/2023</u>
<u>Limited</u>	0.4/4.5/2022

/s/ Carl L. Gordon, Member of 04/17/2023

OrbiMed Capital GP VII LLC

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.